Non-small cell lung cancer market is anticipated to increase in the 7MM from USD 9,730 million in 2017 by 2030. Worldwide, cancer claimed the lives of approximately 9.6 million people in 2018 as per WHO, with lung cancer being the most commonly diagnosed one and accounting for the highest number of deaths (1.76...
Find MoreSanofi’s Isatuximab combo extends lives in multiple myeloma Phase III trials of Sanofi’s investigational anti-CD38 monoclonal antibody, isatuximab combination therapy were successful in lowering down the multiple myeloma tumor rate in 60% of the patients in comparison to 35% reduction in the patients taking the...
Find MoreWORLD NO TOBACCO DAY Every year, 31st May is observed as World Tobacco Day. This day is intended to spread awareness about health issues associated with tobacco use and to encourage the government to adopt effective policies to reduce the use of tobacco products. Every year, approximately 7 million people die du...
Find More[caption id="attachment_3536" align="aligncenter" width="1360"] Lung Cancer Infographic[/caption] Lung cancer is among the leading cause of cancer deaths with the lowest survival rate. Early detection can increase the chances of survival. As November is #LungCancerAwareness Month, we are doing our part by increasin...
Find MoreCancer treatment methodologies are always evolving, and there cannot be any denying to the fact. In this uninterrupted pursuit, old formulas are sometimes used in new ways, arousing hopes for patients as well as commercial treatment providers. A case in point is the usage of light, which has long been used to see ca...
Find MoreAbbVie Receives USFDA Approval for Imbruvica Plus Rituximab as First Chemotherapy-Free Combination Treatment for Waldenström's Macroglobulinemia Adults AbbVie announced that the USFDA approved Imbruvica (ibrutinib) plus rituximab (Rituxan) for the treatment of adult patients with Waldenström's macroglobulinemia (W...
Find MoreFDA Approves Alunbrig (brigatinib) for Rare Lung Cancer Takeda Pharmaceuticals announced the FDA approved Alunbrig (brigatinib) to treat patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. Brigatinib is a kinas...
Find MoreA Chinese group has become the first to inject a person with cells that contain genes edited using the revolutionary CRISPR–Cas9 technique. On 28 October, a team led by oncologist Lu You at Sichuan University in Chengdu delivered the modified cells into a patient with aggressive lung cancer as part of a clinical t...
Find MoreAntibody–drug conjugates (ADCs), a new weapon of 21st Century for fighting Cancer Traditional cancer chemotherapy was having harsh side effects and also leads to systemic toxicity. The approach was also referred to as the carpet-bombing strategy for fighting cancer. Traditional chemotherapy does not discriminate b...
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.